Young-Hwan Hwang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1885576/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment. Kidney Research and Clinical Practice, 2021, 40, S1-S37.	2.2	6
2	Executive Summary of the Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment. Kidney Research and Clinical Practice, 2021, 40, 578-595.	2.2	2
3	Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease. Journal of Korean Medical Science, 2020, 35, e165.	2.5	5
4	Bioelectrical impedance analysis as a nutritional assessment tool in Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2019, 14, e0214912.	2.5	9
5	Genetic Characteristics of Korean Patients with Autosomal Dominant Polycystic Kidney Disease by Targeted Exome Sequencing. Scientific Reports, 2019, 9, 16952.	3.3	7
6	Obesity, Metabolic Abnormality, and Progression of CKD. American Journal of Kidney Diseases, 2018, 72, 400-410.	1.9	105
7	Clinical experience with white blood cellâ€₽ET/CT in autosomal dominant polycystic kidney disease patients with suspected cyst infection: A prospective case series. Nephrology, 2018, 23, 661-668.	1.6	9
8	Frequent patient retraining at home reduces the risks of peritoneal dialysis-related infections: A randomised study. Scientific Reports, 2018, 8, 12919.	3.3	23
9	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. , 2018, , 133-142.		Ο
10	Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease. BMC Nephrology, 2017, 18, 22.	1.8	18
11	Polycystic Kidney Disease without an Apparent Family History. Journal of the American Society of Nephrology: JASN, 2017, 28, 2768-2776.	6.1	75
12	Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Scientific Reports, 2017, 7, 4260.	3.3	27
13	Serum adiponectin and protein–energy wasting in predialysis chronic kidney disease. Nutrition, 2017, 33, 254-260.	2.4	18
14	Baseline Fgf23 is Associated with Cardiovascular Outcome in Incident Pd Patients. Peritoneal Dialysis International, 2016, 36, 26-32.	2.3	16
15	Effect of Simultaneous Nephrectomy on Perioperative Blood Pressure and Graft Outcome in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease. The Journal of the Korean Society for Transplantation, 2016, 30, 24.	0.2	Ο
16	MP047POLYCYSTIC KIDNEY DISEASE 1 GENE MUTATION AMONG SIGNIFICANT POLYCYSTIC LIVER DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i358-i358.	0.7	0
17	Diagnostic performance of 18F-FDG-labeled white blood cell PET/CT for cyst infection in patients with autosomal dominant polycystic kidney disease. Nuclear Medicine Communications, 2016, 37, 493-498.	1.1	16
18	Comparison of volumeâ€reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease. Hepatology Research, 2016, 46, 183-191.	3.4	27

#	Article	IF	CITATIONS
19	HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis. American Journal of Physiology - Renal Physiology, 2016, 310, F342-F350.	2.7	25
20	Normal body mass index with central obesity has increased risk of coronary artery calcification in Korean patients with chronic kidney disease. Kidney International, 2016, 90, 1368-1376.	5.2	16
21	Clinical Trials and a View Toward the Future of ADPKD. Advances in Experimental Medicine and Biology, 2016, 933, 105-121.	1.6	2
22	Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1861-1868.	6.1	123
23	Association of serum adiponectin level with albuminuria in chronic kidney disease patients. Clinical and Experimental Nephrology, 2016, 20, 443-449.	1.6	22
24	Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD. Scientific Reports, 2015, 5, 15238.	3.3	15
25	Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2015, 10, e0144526.	2.5	43
26	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 746-753.	6.1	126
27	Restoring multidrug resistance-associated protein 3 attenuates cell proliferation in the polycystic kidney. American Journal of Physiology - Renal Physiology, 2015, 308, F1004-F1011.	2.7	5
28	Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients. BMC Nephrology, 2015, 16, 86.	1.8	22
29	Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Korean Journal of Medicine, 2015, 89, 169-178.	0.3	3
30	First Case of Continuous Ambulatory Peritoneal Dialysis-Related Peritonitis Caused by Cryptococcus arboriformis. Annals of Laboratory Medicine, 2014, 34, 328-331.	2.5	5
31	Successful Pregnancy in a Patient with Autosomal Dominant Polycystic Kidney Disease on Long-Term Hemodialysis. Journal of Korean Medical Science, 2014, 29, 301.	2.5	13
32	Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease. BMC Medical Genetics, 2014, 15, 129.	2.1	15
33	Utility of QuantiFERON-TB Assay for Prediction of Tuberculosis Development in Kidney Transplant Patients in an Intermediate-Tuberculosis-Burden Country: Lack of Evidence for Enhanced Prediction for Short-Term Tuberculosis Development. Transplantation Proceedings, 2014, 46, 583-587.	0.6	22
34	Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. Human Genetics, 2014, 133, 281-297.	3.8	52
35	Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrology, 2014, 15, 63.	1.8	30
36	KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods. BMC Nephrology, 2014, 15, 80.	1.8	156

#	Article	IF	CITATIONS
37	Comparison of the Efficacy and Safety Profile of Morning Administration of Controlled-release Simvastatin Versus Evening Administration of Immediate-release Simvastatin in Chronic Kidney Disease Patients With Dyslipidemia. Clinical Therapeutics, 2014, 36, 1182-1190.	2.5	12
38	Calpain-mediated proteolysis of polycystin-1 C-terminus induces JAK2 and ERK signal alterations. Experimental Cell Research, 2014, 320, 62-68.	2.6	11
39	Subcutaneous sarcoidosis presenting as a suprapubic mass, acute kidney injury, and hypercalcemia. Korean Journal of Internal Medicine, 2014, 29, 535.	1.7	2
40	Novel three-dimensional imaging volumetry in autosomal dominant polycystic kidney disease: comparison with 2D volumetry. Clinical Nephrology, 2014, 82, 98-106.	0.7	1
41	Calpain-mediated proteolysis of polycystin-1 C-terminus induces JAK2 and ERK signal alterations. Experimental Cell Research, 2014, 320, 62-8.	2.6	6
42	Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrology, 2013, 14, 1.	1.8	78
43	Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrology, 2013, 14, 112.	1.8	31
44	Serum arylhydrocarbon receptor transactivating activity is elevated in type 2 diabetic patients with diabetic nephropathy. Journal of Diabetes Investigation, 2013, 4, 483-491.	2.4	25
45	Successfully Treated <i>Escherichia coli</i> -Induced Emphysematous Cyst Infection with Combination of Intravenous Antibiotics and Intracystic Antibiotics Irrigation in a Patient with Autosomal Dominant Polycystic Kidney Disease. Journal of Korean Medical Science, 2013, 28, 955.	2.5	3
46	Unilateral renal cystic disease in the right kidney. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 435-437.	1.5	4
47	Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2012, 302, F606-F613.	2.7	29
48	The relationship between intracranial arterial stenosis and glomerular filtration rate. Journal of Thrombosis and Thrombolysis, 2012, 34, 310-317.	2.1	3
49	Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study. BMC Nephrology, 2012, 13, 93.	1.8	25
50	Outcome of Early Initiation of Peritoneal Dialysis in Patients with End-Stage Renal Failure. Journal of Korean Medical Science, 2012, 27, 170.	2.5	12
51	Effect of multidisciplinary preâ€dialysis education in advanced chronic kidney disease: Propensity score matched cohort analysis. Nephrology, 2012, 17, 472-479.	1.6	40
52	Design and Implementation of Program for Volumetric Measurement of Kidney. Communications in Computer and Information Science, 2012, , 170-176.	0.5	1
53	Waldenstrom Macroglobulinemia with CD5+ Expression Presented as Cryoglobulinemic Glomerulonephropathy: A Case Report. Journal of Korean Medical Science, 2011, 26, 824.	2.5	8
54	Association of Polymorphisms of Interleukin-8, CXCR1, CXCR2, and Selectin With Allograft Outcomes in Kidney Transplantation. Transplantation, 2011, 91, 57-64.	1.0	7

Young-Hwan Hwang

#	Article	IF	CITATIONS
55	Association between Renal Dysfunction and the Mixed Plaque of Coronary Artery on Computed Tomographic Angiography. Tohoku Journal of Experimental Medicine, 2011, 225, 171-177.	1.2	0
56	Comparison of vascular calcification scoring systems using plain radiographs to predict vascular stiffness in peritoneal dialysis patients. Nephrology, 2011, 16, no-no.	1.6	5
57	Association of complement 5 genetic polymorphism with renal allograft outcomes in Korea. Nephrology Dialysis Transplantation, 2011, 26, 3378-3385.	0.7	20
58	Loss of Residual Renal Function was Not Associated with Glycemic Control in Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2011, 31, 154-159.	2.3	9
59	Pharmacokinetic Profiles of Ceftazidime after Intravenous Administration in Patients Undergoing Automated Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2011, 55, 2523-2527.	3.2	11
60	Central Venous Stenosis Caused by Traction of the Innominate Vein due to a Tuberculosis-Destroyed Lung. Korean Journal of Internal Medicine, 2011, 26, 460.	1.7	1
61	Cardiovascular Diseases after Kidney Transplantation in Korea. Journal of Korean Medical Science, 2010, 25, 1589.	2.5	20
62	An Infrarenal Aortic Hypoplasia Presented with Claudication. Journal of Korean Medical Science, 2010, 25, 950.	2.5	8
63	Assessment of Deceased Donor Kidneys Using a Donor Scoring System. Yonsei Medical Journal, 2010, 51, 870.	2.2	4
64	Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 1639-1646.	0.7	64
65	Association of <i>AHSC</i> Gene Polymorphisms and Aortic Stiffness in Peritoneal Dialysis Patients. American Journal of Nephrology, 2010, 31, 510-517.	3.1	7
66	Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 4041-4048.	0.7	42
67	Effects of Interleukin-6 T15A Single Nucleotide Polymorphism on Baseline Peritoneal Solute Transport Rate in Incident Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 81-88.	2.3	24
68	Transcatheter Arterial Embolization Therapy for a Massive Polycystic Liver in Autosomal Dominant Polycystic Kidney Disease Patients. Journal of Korean Medical Science, 2009, 24, 57.	2.5	21
69	Cyst Formation in Kidney via B-Raf Signaling in the PKD2 Transgenic Mice. Journal of Biological Chemistry, 2009, 284, 7214-7222.	3.4	73
70	Genetic Polymorphisms of Hypoxia-Inducible Factor-1 Alpha and Cardiovascular Disease in Hemodialysis Patients. Nephron Clinical Practice, 2009, 113, c104-c111.	2.3	20
71	Impact of Polymorphisms of TLR4/CD14 and TLR3 on Acute Rejection in Kidney Transplantation. Transplantation, 2009, 88, 699-705.	1.0	37
72	Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29, 81-8.	2.3	17

Young-Hwan Hwang

#	Article	IF	CITATIONS
73	Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2008, 23, 2356-2364.	0.7	24
74	A Case of Treatment with Etanercept in Rheumatoid Arthritis Patient on Hemodialysis. The Journal of the Korean Rheumatism Association, 2008, 15, 317.	0.1	0
75	MCP-1 and RANTES Polymorphisms in Korean Diabetic End-Stage Renal Disease. Journal of Korean Medical Science, 2007, 22, 611.	2.5	16
76	PKD2 gene mutation analysis in Korean autosomal dominant polycystic kidney disease patients using two-dimensional gene scanning. Clinical Genetics, 2006, 70, 502-508.	2.0	9
77	Aggravation of ataxia due to acetazolamide induced hyperammonaemia in episodic ataxia. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 771-772.	1.9	17
78	Characterization of microsatellite markers to diagnose ADPKD. Molecular and Cellular Probes, 2004, 18, 155-159.	2.1	2
79	Three novel mutations of the PKD1 gene in Korean patients with autosomal dominant polycystic kidney disease. Clinical Genetics, 2002, 62, 169-174.	2.0	8
80	Characterization of microsatellite markers adjacent to AP-4 on chromosome 16p13.3. Molecular and Cellular Probes, 2001, 15, 313-315.	2.1	4
81	Genetic heterogeneity in Korean families with autosomal-dominant polycystic kidney disease (ADPKD): the first Asian report. Clinical Genetics, 2001, 60, 138-144.	2.0	6